Phaseline

Companies › CRISM Therapeutics

CRISM Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout May 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
irinotecan-ChemoSeed
Irinotecan-releasing implant for local chemotherapy in glioblastoma resection cavity
SLC22A16Phase 2GlioblastomaMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07356973irinotecan-ChemoSeedPhase 2GlioblastomaOncologyMay 2029

Targets

SLC22A16 (1)

Companies with the same targets

–

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.